In terms of implications for future treatment, there is some support for additive therapy with anti-inflammatory medication for treatment-resistant depression; however, this was only true for patients with low-level inflammation (CRP ≥ 3 mg/L)23–25. This evidence concerns the gene CRP and depressive symptom measurement.